<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04064463</url>
  </required_header>
  <id_info>
    <org_study_id>19-146-2</org_study_id>
    <nct_id>NCT04064463</nct_id>
  </id_info>
  <brief_title>Dual Reinforcement Contingency Management for Alcohol Use Disorders</brief_title>
  <acronym>Peth</acronym>
  <official_title>Dual Reinforcement Contingency Management for Alcohol Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phosphatidylethanol (PEth) is a direct biomarker of alcohol that can detect moderate to heavy&#xD;
      drinking with high sensitivity and specificity over 3-week periods. Reinforcing negative PEth&#xD;
      results alongside attendance may increase the proportion of participants who respond to CM&#xD;
      during and post treatment. In the proposed study, the investigators will collect PEth samples&#xD;
      every 3 weeks for 12 weeks in 150 participants initiating outpatient treatment for alcohol&#xD;
      use disorders. Using a two-group randomized design, participants will be assigned to standard&#xD;
      care with PEth monitoring alone or with CM for attending treatment and submitting PEth&#xD;
      negative samples. Compared to standard care and monitoring, the investigators expect that the&#xD;
      CM intervention will result in greater attendance, more PEth negative samples, and higher&#xD;
      proportions of self-reported non-drinking days, along with lower proportions of heavy&#xD;
      drinking days, over the short term and the long term, measured throughout a 12-month&#xD;
      follow-up. The investigators anticipate that the reinforcement intervention may decrease&#xD;
      other drug use and sexual risk behaviors that spread HIV, reduce psychiatric symptoms, and&#xD;
      improve quality of life as well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Group attendance</measure>
    <time_frame>12 weeks</time_frame>
    <description>longest consecutive days attended groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol abstinence</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of negative PEth samples</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Contingency Management</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care plus contingency management</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>standard treatment for substance use disorders, along with sample monitoring</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Contingency management</intervention_name>
    <description>Participants can earn reinforcement for attending group and abstinence from alcohol</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  in intensive outpatient treatment&#xD;
&#xD;
          -  DSM-5 diagnosis of an alcohol use disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have a condition that may hinder study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Alessi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Fetter</last_name>
    <phone>860-679-4556</phone>
    <email>fetter@uchc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Village</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Fetter</last_name>
      <phone>860-679-4556</phone>
      <email>fetter@Uchc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Sheila Alessi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

